Preoperative oral treatment with lactulose is used to prevent complications after surgery in patients with obstructive jaundice. The effect is perhaps the result of an inactivation of gut derived endotoxins but the exact mechanism of action is, however, unknown. Tumour necrosis factor is an important mediator of endotoxin toxicity. The cytokine tumour necrosis factor is mainly produced by mononuclear phagocytes. In this study, the effect of lactulose on the endotoxin induced tumour necrosis factor release by monocytes was investigated. The direct effect of lactulose on endotoxin was tested in a chromogenic limulus amoebocyte lysate assay. Polymyxin B a known inactivator of endotoxin was used as control in both experiments. Lactulose has a limited capacity to inactivate endotoxin as measured in the endotoxin assay. In contrast lactulose significantly reduced endotoxin induced tumour necrosis factor production by monocytes. In conclusion lactulose inhibits tumour necrosis factor production by a direct inhibitory effect on monocytes, rather than by inactivation of endotoxin. Because tumour necrosis factor is an important mediator of endotoxin toxicity, this inhibitory effect could explain the beneficial effect of lactulose in obstructive jaundice.
Gut derived endotoxins are thought to be responsible for postoperative complications such as renal insufficiency, gastrointestinal bleeding and infections, in patients with obstructive jaundice. 2 This theory is supported by the high incidence of endotoxaemia reported in these patients and the correlation that was found between the presence of endotoxaemia and occurrence of complications. -5 Polymyxin B is a known antiendotoxin agent65 and reduces mortality in rats, with experimental biliary obstruction, challenged with intragastric endotoxin.9 Unfortunately, because of its renal toxicity, effective doses cannot be given to jaundiced patients.'0 Orally administrated bile acids have been used successfully to prevent endotoxin related complications after surgery in jaundiced patients" 12 bile acids reduced absorption of endotoxins from the gastrointestinal tract resulting in a decrease of portal and systemic endotoxaemia and of postoperative renal complications.
Preoperative oral treatment with lactulose was found to be equally effective in preventing postoperative renal complications in patients with obstructive jaundice.'3 The effect of lactulose was explained by an inactivation of endotoxins from the gastrointestinal tract. Suggestive evidence for this hypothesis was the reduced limulus amoebocyte lysate activation by endotoxin in the presence of lactulose.'3'4 The mechanism through which lactulose reduces endotoxin toxicity, however, remains to be further clarified.
Tumour necrosis factor is reported to be an important mediator of endotoxin toxicity.'5-" The cytokine tumour necrosis factor is mainly produced by mononuclear phagocytes in response to endotoxin.'8 9 These findings enabled us to develop an in vitro model to study the effect of different agents on the production of tumour necrosis factor as the mediator of endotoxin toxicity. Human peripheral blood monocytes were stimulated with endotoxin in the presence of the compound to be tested and tumour necrosis factor production was measured with an enzyme linked immunosorbent assay (ELISA).
To analyse if and how lactulose prevents the toxic effects of endotoxin, this in vitro model was used. The direct effect of lactulose on endotoxin was evaluated with a modified chromogenic limulus amoebocyte lysate assay. As lactulose preparations used in clinical practice can be divided in two groups, a crystalline pure lactulose and lactulose syrup containing galactose and lactose besides lactulose, both preparations were tested. 
Methods

CELL CULTURE EXPERIMENTS
The isolated monocytes, as described above, were allowed to settle for two hours after which culture medium was replaced with culture medium to which combinations of lipopolysaccharide, phorbol myristate acid, crystalline lactulose, lactulose syrup, lactitol, and Polymyxin B were added. In the first series of experiments a serial dilution of lipopolysaccharide was preincubated for two hours with crystalline lactulose, lactulose syrup, lactitol, or Polymyxin B. In the second series of experiments different concentrations of crystalline lactulose, lactulose syrup, and Polymyxin B were preincubated for two hours with a serial dilution of lipopolysaccharide. In the third series of experiments phorbol myristate acid was used to stimulate the tumour necrosis factor production of monocytes, again after preincubation for two hours with crystalling lactulose, lactulose syrup, lactitol, and Polymyxin B. In both experiments monocytes stimulated with lipopolysaccharide or phorbol myristate acid in culture medium served as positive controls whereas monocytes cultured in culture medium were used as negative controls. All cultures were performed at 37°C in a moist 8% carbon dioxide air atmosphere. Lactulose syrup, crystalline lactulose, and lactitol used in the cell culture experiments were diluted in pyrogen free water in order to reach an osomolarity of 300 mosmol. Thereafter lactulose syrup was diluted in culture medium to obtain a concentration of ± 7 mg/ml of lactulose. Crystalline lactulose and lactitol were diluted in culture medium to a concentration of ± 10 mg/ ml. The difference in lactulose content between the two lactulose solutions is caused by the presence of the monosaccharides lactose and galactose which account for 30% of the osmolarity of undiluted lactulose syrup. In all experiments osmolarity and pH of culture medium after addition of the different compounds were determined. Osmolarity ranged from 300 to 320 mosmol, pH from 7-14 to 7.24. The values of culture medium were 307 mosmol and pH 7-15. Endotoxin dosages of 1 ng lipopolysaccharide/ml caused tumour necrosis factor productions which were on average above 1000 pg/ml (Figs  1-3) . The tumour necrosis factor production rapidly increased at higher lipopolysaccharide dosages reaching a plateau at 30-100 ng lipopolysaccharide/ml, after which a much slower increase of tumour necrosis factor production in relation to the lipopolysaccharide dose was found. Measuring tumour necrosis factor production by monocytes was a highly sensitive and reproducible way to detect the presence of biological active lipopolysaccharide.
Both lactulose preparations inhibited tumour necrosis factor production by monocytes after stimulation with endotoxin significantly (Fig 1) . Lactulose syrup appeared to be a more effective inhibitor of tumour necrosis factor production, than crystalline lactulose. At 7 mg lactulose/ml lactulose syrup reduced lipopolysaccharide induced tumour necrosis factor production by monocytes with 95% at all concentrations of lipopolysaccharide used, whereas crystalline lactulose in similar concentrations reduced tumour necrosis factor production with 15-20%. Lactitol at 10 mg/ml did not inhibit endotoxin induced tumour necrosis factor production by monocytes (data not shown in figure) . As dose of endotoxin, after which tumour necrosis factor production of Polymyxin B treated cells paralleled that of control monocytes (Fig 4) .
TUMOUR NECROSIS FACTOR PRODUCTION BY MONOCYTES AFTER STIMULATION WITH PHORBOL MYRISTATE ACID, EFFECT OF LACTULOSE, LACTITOL AND POLYMYXIN B
To further analyse the effect of both lactulose preparations, lactitol, and Polymyxin B, on tumour necrosis factor production by monocytes, the phorbol myristate acid induced tumour necrosis factor production by monocytes was studied. Phorbol myristate acid induces tumour necrosis factor production by an activation of the intracellular messenger protein kinase C.
After stimulation with phorbol myristate acid monocytes produced high amounts of tumour necrosis factor. Crystalline lactulose and lactulose syrup in concentrations shown, significantly reduced phorbol myristate acid induced tumour necrosis factor production by monocytes (Fig 5) . This reduction was equivalent to the inhibitory effect of both crystalline lactulose and lactulose syrup on endotoxin induced tumour necrosis factor production by monocytes. Lactitol did not inhibit phorbol myristate acid induced tumour necrosis factor production.
Polymyxin B did not affect phorbol myristate acid induced tumour necrosis factor production by monocytes, this in contrast to the endotoxin induced tumour necrosis factor production.
VIABILITY OF THE MONOCYTES AFTER THE EXPERIMENTS
After the cell culture experiments the viability of the monocytes was tested by trypan blue exclusion and phagocytosis of latex beads. Directly after removing supernatants for tumour necrosis factor measurements trypan blue solution or latex beads in culture medium were added to the cell cultures. Trypan blue exclusion was greater than 85% in all experiments. Phagocytosis of latex beads was clearly delayed, but not significantly reduced, after incubation with lactulose syrup whereas preincubation with crystalline lactulose or Polymyxin B did not affect phagocytosis as compared with control cells.
Discussion
The results of our experiments show that crystalline lactulose (Legendal) did not inactivate endotoxin as determined with the limulus amoebocyte lysate assay. Lactulose syrup (Duphalac) did inactivate low amounts of lipopolysaccharide, this effect decreased with increasing lipopolysaccharide concentrations.
Both lactulose syrup and crystalline lactulose inhibited tumour necrosis factor production of monocytes stimulated with lipopolysaccharide significantly. Polymyxin B also inhibited tumour necrosis factor production by monocytes after stimulation with endotoxin but the kinetics were monocytes was not affected. Lactitol a disaccharide clinically used for similar indications as lactulose did not reduce tumour necrosis factor production by monocytes, indicating that the observed inhibitory effect is specific for lactulose. Experiments with phorbol myristate acid, a direct stimulator of tumour necrosis factor production by monocytes which acts through activation of the intracellular messenger protein kinase C, supplied further evidence for a direct inhibitor effect of lactulose on monocytes. Both lactulose preparations inhibited the phorbol myristate acid induced tumour necrosis factor production by monocytes in a fashion similar to the inhibition of lipopolysaccharide induced tumour necrosis factor production. In contrast Polymyxin B, as expected, did not reduce tumour necrosis factor production by monocytes stimulated with phorbol myristate acid.
The data show that both lactulose preparations inhibit lipopolysaccharide induced as well as phorbol myristate acid induced tumour necrosis factor production by monocytes. In all cell culture experiments, however, lactulose syrup was more effective than similar amounts of crystalline lactulose in reducing tumour necrosis factor production by monocytes.
The effect of Polymyxin B as described in our experiments is similar to results of a study by Duff et al.24 In these experiments the effect of Polymyxin B on production of endogenous pyrogen by monocytes after stimulation with endotoxin was studied. They found that lipopolysaccharide induced production of endogenous pyrogen was inhibited by Polymyxin B, whereas production ofendogenous pyrogen after stimulation of monocytes Orally administrated lactulose prevented endotoxin related complications after surgery in jaundiced patients. 3 Moreover galactosamine induced liver necrosis, caused by endotoxins from the gastrointestinal tract, was prevented by oral pretreatment with lactulose.'4 Both studies reported a strongly reduced activation of the limulus amoebocyte lysate assay by endotoxin in presence of lactulose but these data differ from our observations. We found that lactulose inactivates only small amounts of endotoxin.
The results of our study indicate, however, that the efficacy of lactulose can be explained by a direct effect on mononuclear phagocytes resulting in a reduced production of the mediator of endotoxin toxicity. Lehman et al showed that tumour necrosis factor appeared to be a central mediator of endotoxin mediated mortality in mice treated with D-galactosamine and endotoxin. '9 These results indicate that inhibition of tumour necrosis factor production can prevent endotoxin induced complications.
That lactulose treatment not only causes an acidification and/or hyperosmolarity of the bowel lumen, but can also have an effect on metabolism of bacteria and different cells in the bowel wall was suggested by a number of studies on lactulose treatment of hepatic encephalopathy in patients with liver cirrhosis. Diminished ammonia production after lactulose treatment was explained by alteration of bacterial flora in the gut, by changes of bacterial metabolism, and recently by an effect of lactulose on metabolism of crypt and villus cells of the bowel wall. 26 30 Lactulose under normal conditions is only absorbed in small amounts from the gastrointestinal tract (approximately 1-5% of the administrated oral dose is excreted in urine)." In situations of mucosal damage, stress, or infection, however, the absorption of lactulose from the bowel is greatly increased.32-34 It is in these situations where substantial amounts of lactulose penetrate the bowel wall that it is probably most effective. Our observations show that lactulose can have a direct effect on cell function. Lactulose inhibited the release of tumour necrosis factor, the mediator of endotoxin toxicity, by an inhibitory effect on mononuclear phagocytes. The effect of lactulose could not be explained by an inactivation of endotoxin. Hypothetically this inhibitory effect of lactulose on the production of tumour necrosis factor may explain the beneficial effect of lactulose as supportive preoperative treatment in jaundiced patients.
